Gnosis by Lesaffre has launched a new product in its probiotic range called LifeinU L. rhamnosus GG 350, which is a new quality specification of its existing reference probiotic bacteria, LifeinU L. rhamnosus GG.
Gnosis by Lesaffre (Marcq-en-Baroeul, France, and East Brunswick, NJ) has launched a new product in its probiotic range called LifeinU L. rhamnosus GG 350, which is a new quality specification of its existing reference probiotic bacteria, LifeinU L. rhamnosus GG. Lactobacillus rhamnosus GG is a strain used worldwide to help restore and maintain a balanced gastrointestinal flora and protect the gut from antibiotic-associated diarrhea as well as acute diarrhea.
The new quality specification, in line with current market standards of 350.109 CFU/g, is the product of significant time and resources. The company’s proprietary production process also ensures stability over time.
“This launch represents an important step for Gnosis and Lesaffre Group, as it underscores our commitment to developing a comprehensive bacterial offering that covers all microorganism kingdoms, including yeast, bacteria, and bacteriophages,” said Philippe Caillat, Gnosis’s global marketing director, in a press release. “We believe that this approach will enable us to offer our customers a truly integrated and holistic approach to microbiome health.”
“As Gnosis is committed to sustainability, the biotransformation process that we use to produce LifeinU L. rhamnosus GG 350 is a promising opportunity for industries to reduce their raw material consumption and operate more sustainably,” Caillat added. “We believe that this approach enables industries to reduce their impact on the environment while encouraging customers to consume more responsibly.”